- Home
- ICON vs PALI Comparison
ICON vs PALI Comparison
Compare ICON & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICON
- PALI
- Stock Information
- Founded
- ICON 2023
- PALI 1996
- Country
- ICON Greece
- PALI United States
- Employees
- ICON N/A
- PALI N/A
- Industry
- ICON
- PALI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICON
- PALI Health Care
- Exchange
- ICON Nasdaq
- PALI Nasdaq
- Market Cap
- ICON 5.2M
- PALI 5.0M
- IPO Year
- ICON 2024
- PALI N/A
- Fundamental
- Price
- ICON $2.37
- PALI $1.04
- Analyst Decision
- ICON Strong Buy
- PALI Strong Buy
- Analyst Count
- ICON 1
- PALI 2
- Target Price
- ICON $4.50
- PALI $12.00
- AVG Volume (30 Days)
- ICON 206.5K
- PALI 1.2M
- Earning Date
- ICON 09-09-2025
- PALI 08-15-2025
- Dividend Yield
- ICON 396.62%
- PALI N/A
- EPS Growth
- ICON N/A
- PALI N/A
- EPS
- ICON N/A
- PALI N/A
- Revenue
- ICON $6,137,000.00
- PALI N/A
- Revenue This Year
- ICON $51.78
- PALI N/A
- Revenue Next Year
- ICON $51.90
- PALI N/A
- P/E Ratio
- ICON N/A
- PALI N/A
- Revenue Growth
- ICON 16.93
- PALI N/A
- 52 Week Low
- ICON $1.60
- PALI $0.60
- 52 Week High
- ICON $130.80
- PALI $4.32
- Technical
- Relative Strength Index (RSI)
- ICON N/A
- PALI 58.06
- Support Level
- ICON N/A
- PALI $0.95
- Resistance Level
- ICON N/A
- PALI $1.40
- Average True Range (ATR)
- ICON 0.00
- PALI 0.16
- MACD
- ICON 0.00
- PALI 0.00
- Stochastic Oscillator
- ICON 0.00
- PALI 47.06
About ICON Icon Energy Corp. Common stock
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.